[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 39 of about 39
1. Cereda S, Passoni P, Reni M, Viganò MG, Aldrighetti L, Nicoletti R, Villa E: The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma. Cancer; 2010 May 1;116(9):2208-14
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.
  • BACKGROUND: Biliary tract adenocarcinoma (BTA) is an uncommon tumor with a poor prognosis and no standard, systemic chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biliary Tract Neoplasms / drug therapy

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • (PMID = 20187098.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Marchesi F, Piemonti L, Fedele G, Destro A, Roncalli M, Albarello L, Doglioni C, Anselmo A, Doni A, Bianchi P, Laghi L, Malesci A, Cervo L, Malosio M, Reni M, Zerbi A, Di Carlo V, Mantovani A, Allavena P: The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res; 2008 Nov 1;68(21):9060-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma.
  • Tumor perineural dissemination is a hallmark of human pancreatic ductal adenocarcinoma (PDAC) and represents a major source of local tumor recurrence after surgery.
  • [MeSH-major] Adenocarcinoma / pathology. Nervous System / pathology. Pancreatic Neoplasms / pathology. Receptors, Chemokine / physiology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18974152.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD29; 0 / CX3CR1 protein, human; 0 / Receptors, Chemokine; EC 3.6.1.- / GTP-Binding Proteins
  •  go-up   go-down


3. Hokaiwado N, Takeshita F, Naiki-Ito A, Asamoto M, Ochiya T, Shirai T: Glutathione S-transferase Pi mediates proliferation of androgen-independent prostate cancer cells. Carcinogenesis; 2008 Jun;29(6):1134-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We here utilized androgen-dependent/independent transplantable tumors, newly established with the 'transgenic rat adenocarcinoma in prostate' (TRAP) model, to analyze their gene expression using microarrays.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Probes. 2000 Aug;14(4):211-7 [10970725.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9248-57 [17909032.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4693-700 [11406539.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4820-6 [11406558.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2727-30 [11555585.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1815-26 [11696442.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8611-6 [11751372.001]
  • [Cites] Carcinogenesis. 2002 Mar;23(3):463-7 [11895861.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):34-45 [11900250.001]
  • [Cites] Jpn J Cancer Res. 2002 Jul;93(7):767-73 [12149142.001]
  • [Cites] Nat Biotechnol. 2002 Oct;20(10):1006-10 [12244328.001]
  • [Cites] Cancer Detect Prev. 2002;26(5):376-80 [12518868.001]
  • [Cites] Prostate. 2003 May 15;55(3):199-205 [12692786.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2673-7 [12855646.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3919-22 [12873985.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):2897-902 [12926131.001]
  • [Cites] J Surg Res. 2003 Jul;113(1):102-8 [12943817.001]
  • [Cites] J Natl Cancer Inst. 2003 Nov 5;95(21):1634-7 [14600096.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Nov 21;311(3):786-92 [14623342.001]
  • [Cites] J Urol. 2004 Jun;171(6 Pt 1):2195-8 [15126784.001]
  • [Cites] Oncogene. 2004 May 13;23(22):3945-52 [15007384.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2002;5(1):22-7 [15195126.001]
  • [Cites] Urology. 2004 Oct;64(4):821-5 [15491741.001]
  • [Cites] Prostate. 2004 Dec 1;61(4):332-53 [15389811.001]
  • [Cites] Jpn J Cancer Res. 1988 May;79(5):573-5 [3136108.001]
  • [Cites] Cancer Lett. 1990 Nov 19;55(1):25-9 [2245407.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11733-7 [7972132.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jun;6(6):443-50 [9184779.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5275-80 [9560266.001]
  • [Cites] Oncogene. 1999 Feb 11;18(6):1313-24 [10022813.001]
  • [Cites] Nat Med. 1999 Jun;5(6):707-10 [10371512.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):176-81 [15668493.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):347-57 [15602745.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12177-82 [16091473.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9485-94 [16230413.001]
  • [Cites] Cancer Sci. 2006 Aug;97(8):689-96 [16863503.001]
  • [Cites] Urology. 2007 Jan;69(1):11-6 [17270599.001]
  • [Cites] Cancer Detect Prev. 2007;31(1):59-63 [17291695.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1394-401 [17555796.001]
  • [Cites] Int J Cancer. 2001 May 20;95(3):152-5 [11307147.001]
  • (PMID = 18413363.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgens; 0 / RNA, Small Interfering; EC 2.5.1.18 / Glutathione S-Transferase pi
  • [Other-IDs] NLM/ PMC2443274
  •  go-up   go-down


Advertisement
4. Cadieux PA, Mikolajczak SA, Reeves J, Strathdee C, Reid G, Panchal CJ, Clarke MW: Rat PSP94 inhibits the growth and viability of the rat adenocarcinoma cell line PAIII in vitro. Cancer Invest; 2006 Apr-May;24(3):246-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rat PSP94 inhibits the growth and viability of the rat adenocarcinoma cell line PAIII in vitro.
  • To further validate this potential and investigate the protein within a homologous setting, we examined the effects of rat PSP94 on the growth of the rat prostate adenocarcinoma cell line PAIII in vitro.
  • To generate rat PSP94, we used both a plasmid-based expression system and a recombinant rat PSP molecule.
  • Rat PSP was shown to inhibit the growth and survival of PAIII cells in a dose-dependent manner with > 90 percent reductions in both observed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Cell Proliferation / drug effects. Prostatic Neoplasms / drug therapy. Prostatic Secretory Proteins / pharmacology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16809150.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Prostatic Secretory Proteins; 0 / Recombinant Proteins; 0 / beta-microseminoprotein
  •  go-up   go-down


5. Seeni A, Takahashi S, Takeshita K, Tang M, Sugiura S, Sato SY, Shirai T: Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac J Cancer Prev; 2008 Jan-Mar;9(1):7-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model.
  • Since it was recently proposed as a potential prostate cancer chemopreventive agent, we here performed an in vivo experiment to explore its effect in the Transgenic Rat for Adenocarcinoma of Prostate (TRAP) model, featuring the rat probasin promoter/SV 40 T antigen.
  • [MeSH-major] Adenocarcinoma / drug therapy. Anticarcinogenic Agents / therapeutic use. Disease Models, Animal. Prostatic Neoplasms / drug therapy. Stilbenes / therapeutic use

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. RESVERATROL .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18439064.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Androgen Receptor Antagonists; 0 / Angiogenesis Inhibitors; 0 / Anticarcinogenic Agents; 0 / RNA, Messenger; 0 / Receptors, Androgen; 0 / Stilbenes; 0 / Ubiquitin; 0 / trypsin-like serine protease; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; EC 3.4.21.- / Serine Endopeptidases; Q369O8926L / resveratrol
  •  go-up   go-down


6. Moen I, Øyan AM, Kalland KH, Tronstad KJ, Akslen LA, Chekenya M, Sakariassen PØ, Reed RK, Stuhr LE: Hyperoxic treatment induces mesenchymal-to-epithelial transition in a rat adenocarcinoma model. PLoS One; 2009;4(7):e6381
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperoxic treatment induces mesenchymal-to-epithelial transition in a rat adenocarcinoma model.
  • We report that hyperbaric oxygen (HBO) treatment induced mesenchymal-to-epithelial transition (MET) in a dimethyl-alpha-benzantracene induced mammary rat adenocarcinoma model, and the MET was associated with extensive coordinated gene expression changes and less aggressive tumors.
  • [MeSH-major] Adenocarcinoma / pathology. Epithelial Cells / cytology. Hyperoxia / drug therapy. Mesoderm / cytology. Models, Biological

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2008 Dec;44(18):2766-73 [18990559.001]
  • [Cites] Genes Dev. 2000 Mar 15;14(6):704-18 [10733530.001]
  • [Cites] FASEB J. 2003 Sep;17(12):1756-8 [12958200.001]
  • [Cites] Cancer Lett. 2004 Jul 8;210(1):35-40 [15172118.001]
  • [Cites] QJM. 2004 Jul;97(7):385-95 [15208426.001]
  • [Cites] Br J Cancer. 1995 Nov;72(5):1120-4 [7577456.001]
  • [Cites] Oncogene. 2005 Aug 29;24(37):5764-74 [16123809.001]
  • [Cites] Med Sci Monit. 2005 Sep;11(9):RA279-89 [16127374.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):499-508 [16107313.001]
  • [Cites] Wound Repair Regen. 2005 Nov-Dec;13(6):558-64 [16283871.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6B):3833-42 [16312043.001]
  • [Cites] J Cell Biol. 2006 Mar 27;172(7):973-81 [16567498.001]
  • [Cites] BMC Cancer. 2007;7:23 [17263869.001]
  • [Cites] FEBS J. 2007 Mar;274(6):1393-418 [17302740.001]
  • [Cites] Cells Tissues Organs. 2007;185(1-3):7-19 [17587803.001]
  • [Cites] Expert Opin Ther Targets. 2007 Aug;11(8):1055-69 [17665978.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 28;104(35):13966-71 [17715296.001]
  • [Cites] J Neurol Sci. 2007 Nov 15;262(1-2):122-30 [17720201.001]
  • [Cites] J Neurooncol. 2007 Nov;85(2):191-202 [17557137.001]
  • [Cites] Oncologist. 2008;13 Suppl 3:21-6 [18458121.001]
  • [Cites] Dev Cell. 2008 Jun;14(6):818-29 [18539112.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2008 Jul;40(7):643-50 [18604456.001]
  • [Cites] PLoS One. 2008;3(10):e3368 [18852876.001]
  • [Cites] J Biol Chem. 2008 Nov 28;283(48):33437-46 [18832382.001]
  • [Cites] Carcinogenesis. 2008 Dec;29(12):2267-78 [18791199.001]
  • [Cites] Am J Physiol Renal Physiol. 2009 Apr;296(4):F847-58 [19158346.001]
  • [Cites] J Cell Biol. 1999 Nov 1;147(3):631-44 [10545506.001]
  • [Cites] Annu Rev Cell Dev Biol. 1999;15:551-78 [10611972.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):88-92 [10638972.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):76-83 [10655586.001]
  • [Cites] J Cell Biol. 2000 Feb 21;148(4):779-90 [10684258.001]
  • [Cites] Bioinformatics. 2001 Apr;17(4):369-70 [11301307.001]
  • [Cites] Breast Cancer Res. 2001;3(5):289-93 [11597316.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] J Clin Invest. 2002 Aug;110(3):341-50 [12163453.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Cell. 2003 Feb 21;112(4):535-48 [12600316.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):21113-23 [12665527.001]
  • [Cites] Gut. 2009 Mar;58(3):404-12 [18978174.001]
  • (PMID = 19636430.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2712688
  •  go-up   go-down


7. Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Fugazza C, Mazza E, Zerbi A, Di Carlo V, Villa E: Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer; 2009 Jun 15;115(12):2630-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / drug therapy. CA-19-9 Antigen / blood. Pancreatic Neoplasms / blood. Pancreatic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • (PMID = 19353729.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen
  •  go-up   go-down


8. Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Zerbi A, Nicoletti R, Mazza E, Arcidiacono PG, Di Carlo V, Villa E: Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol; 2009 Nov;64(6):1253-9
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
  • PURPOSE: The role and timing of chemotherapy and radiation for treating stage III pancreatic adenocarcinoma remains controversial.
  • METHODS: Treatment-naive patients with stage III non-resectable pancreatic adenocarcinoma were treated with PEFG/PEXG (cisplatin, epirubicin, 5-fluorouracil (F)/capecitabine (X), gemcitabine) or PDXG (docetaxel substituting epirubicin) regimen for 6 months followed by radiotherapy (50-60 Gy) with concurrent F or X or G.
  • CONCLUSION: Combination chemotherapy with four-drug regimens followed by chemoradiation was a feasible strategy showing relevant results in stage III pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19381632.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Reni M, Cereda S, Bonetto E, Viganò MG, Passoni P, Zerbi A, Balzano G, Nicoletti R, Staudacher C, Di Carlo V: Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol; 2007 Feb;59(3):361-7
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma.
  • BACKGROUND: PEFG regimen (cisplatin and epirubicin 40 mg/m2 day 1, gemcitabine 600 mg/m2 days 1 and 8, 5-fluorouracil (FU) 200 mg/m2/day continuous infusion) significantly improved the outcome of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine in a previous phase III trial.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16807732.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Mancosu P, Bettinardi V, Passoni P, Gusmini S, Cappio S, Gilardi MC, Cattaneo GM, Reni M, Del Maschio A, Di Muzio N, Fazio F: Contrast enhanced 4D-CT imaging for target volume definition in pancreatic ductal adenocarcinoma. Radiother Oncol; 2008 Jun;87(3):339-42
Hazardous Substances Data Bank. Iodixanol .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contrast enhanced 4D-CT imaging for target volume definition in pancreatic ductal adenocarcinoma.
  • A procedure to improve target volume definition in pancreatic ductal adenocarcinoma by contrast enhanced 4D-CT imaging has been implemented for radiotherapy planning.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486253.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Triiodobenzoic Acids; 92339-11-2 / iodixanol
  •  go-up   go-down


11. Reni M, Cereda S, Bonetto E, Viganò MG, Passoni P, Zerbi A, Balzano G, Nicoletti R, Staudacher C, Di Carlo V: Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study. Cancer Invest; 2007;25(7):594-8
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study.
  • The aim of this study was to assess the maximum tolerated dose (MTD) of an intensified PEFG regimen administered every 14 days to patients with Stage III or metastatic pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852117.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Reni M, Sartori N, Mambrini A, Berardi R, Passardi A, Milella M, Cereda S, Tronconi MC, Aprile G, Cordio S, Pasetto LM, Rognone A, Pederzoli P, Falconi M: An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change? Anticancer Drugs; 2010 Apr;21(4):459-64
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?
  • A series of 650 patients treated between 1997 and 2007 at 10 Italian centers was analyzed to assess treatment trends and efficacy in stage III pancreatic adenocarcinoma.
  • The inclusion criteria were pathological diagnosis of stage III pancreatic adenocarcinoma; age more than 18 years, Eastern Cooperative Oncology Group performance status less than 3, and no past therapy.
  • The use of a strategy consisting of a gemcitabine-platinating agent containing chemotherapy followed by consolidation chemoradiation has been increasing over time and may represent a suitable choice in the therapeutic management of stage III pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20110805.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


13. Reni M, Berardi R, Mambrini A, Pasetto L, Cereda S, Ferrari VD, Cascinu S, Cantore M, Mazza E, Grisanti S: A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol; 2008 Sep;62(4):673-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma.
  • INTRODUCTION: Limited information on second-line treatment in patients with pancreatic adenocarcinoma is available.
  • Inclusion criteria were: cytological or histologic diagnosis of pancreatic adenocarcinoma and prior gemcitabine-including chemotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Pancreatic Neoplasms / therapy. Salvage Therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18172650.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


14. Ghiuzeli CM, Roussos ET, Wyckoff JB, Sun D, Wang Y, Patsialou T, Goswami S, Gertler FB, Condeelis JS: Evaluation of Mena isoforms as a surrogate for epithelial mesenchymal transformation and erlotinib resistance in breast carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):1078

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The animal models used were the polyoma middle T antigen (PyMT) transgenic mouse and severe combined immunodeficiency (SCID) xenografted tumors derived from injection with a human breast carcinoma line, MDA-MB-231, and a rat adenocarcinoma line, MTLn3, with forced expression of Mena<sup>INV</sup> and Mena11a.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961202.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Cereda S, Rognone A, Ghidini M, Rezzonico S, Passoni P, Mazza E, Nicoletti R, Zerbi A, Villa E, Reni M: A randomized phase II trial of two different four-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel. J Clin Oncol; 2009 May 20;27(15_suppl):4614

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of two different four-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel.
  • : 4614 Background: The combination of cisplatin (P), epirubicin (E), 5-fluorouracil (F) and gemcitabine (G) (PEFG regimen) yielded a progression-free survival at 6 months from treatment start (PFS6) of about 50% and a 1-year overall survival (OS) around 40% in patients with advanced pancreatic adenocarcinoma (PA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964185.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Reni M, Cereda S, Aprile G, Tronconi MC, Milandri C, Passoni P, Rognone A, Balzano G, Di Carlo V, Villa E: A randomized phase II trial of adjuvant chemotherapy with cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG regimen) or gemcitabine alone after curative resection for pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4608

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4608 Background: The PEFG regimen yielded a statistically relevant outcome advantage as compared with gemcitabine (G) in patients with advanced pancreatic adenocarcinoma (PA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964177.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Reni M, Bonetto E, Cordio S, Passoni P, Milandri C, Cereda S, Spreafico A, Galli L, Bordonaro R, Staudacher C, Di Carlo V, Johnson CD: Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial. Pancreatology; 2006;6(5):454-63
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial.
  • BACKGROUND: A phase III trial suggested that a PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen might improve the outcome compared to gemcitabine in advanced pancreatic adenocarcinoma.
  • CONCLUSION: Clinically relevant improvement in QOL from baseline was observed more often after PEFG than after gemcitabine, suggesting that the PEFG regimen did not impair QOL, Partial response was associated with improved QOL suggesting that effective treatment of pancreatic adenocarcinoma may have an important role in these patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy. Quality of Life

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel and IAP.
  • (PMID = 16847383.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Reni M, Passoni P, Bonetto E, Balzano G, Panucci MG, Zerbi A, Ronzoni M, Staudacher C, Villa E, Di Carlo V: Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma. Oncology; 2005;68(2-3):239-45
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma.
  • BACKGROUND: Postoperative management of patients with pancreatic adenocarcinoma (PA) is controversial.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16015040.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Tieva A, Bergh A, Damber JE: Alteration of gonadotropin-releasing hormone receptor expression with the progression of prostate cancer in the Dunning rat adenocarcinoma sublines. Acta Oncol; 2005;44(3):299-303
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration of gonadotropin-releasing hormone receptor expression with the progression of prostate cancer in the Dunning rat adenocarcinoma sublines.
  • The aim was therefore to investigate the variation of GnRH-R expression with prostate tumour progression using Dunning rat adenocarcinoma sublines representing different prostate tumour grades.
  • GnRH-R levels were quantified in the rat dorsolateral (DLP) and Dunning sublines (PAP, AT-1, AT-2, AT-3, MatLyLu) using competitive RT-PCR and Western blot.
  • Our data demonstrate the expression of GnRH-R in normal rat DLP and in different Dunning sublines.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology. Receptors, LHRH / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16076703.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, LHRH
  •  go-up   go-down


20. Dill AL, Ifa DR, Manicke NE, Ouyang Z, Cooks RG: Mass spectrometric imaging of lipids using desorption electrospray ionization. J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Sep 15;877(26):2883-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESI-MS has been used to image a variety of tissue samples including human liver adenocarcinoma, rat brain, human breast tissue and canine abdominal tumor tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Mass Spectrom. 2008 Apr;19(4):531-43 [18258448.001]
  • [Cites] Nat Protoc. 2008;3(3):517-24 [18323820.001]
  • [Cites] Anal Chem. 2008 Jun 15;80(12):4575-82 [18473485.001]
  • [Cites] Anal Chem. 2008 Jul 1;80(13):5168-77 [18481874.001]
  • [Cites] Science. 2008 Aug 8;321(5890):805 [18687956.001]
  • [Cites] Rapid Commun Mass Spectrom. 2008 Sep;22(17):2639-44 [18666197.001]
  • [Cites] Anal Chem. 2008 Nov 1;80(21):7921-9 [18844371.001]
  • [Cites] Anal Chem. 2008 Dec 1;80(23):8865-70 [19040400.001]
  • [Cites] Anal Chem. 2000 Feb 15;72(4):652-7 [10701247.001]
  • [Cites] Anal Chem. 2000 Nov 1;72(21):5239-43 [11080870.001]
  • [Cites] Nat Med. 2001 Apr;7(4):493-6 [11283679.001]
  • [Cites] J Mass Spectrom. 2001 Apr;36(4):355-69 [11333438.001]
  • [Cites] Free Radic Biol Med. 2002 Sep 1;33(5):620-6 [12208348.001]
  • [Cites] Indian J Exp Biol. 2002 Jun;40(6):656-67 [12587714.001]
  • [Cites] J Mass Spectrom. 2003 Jul;38(7):699-708 [12898649.001]
  • [Cites] Anal Chem. 2003 Jul 15;75(14):3429-34 [14570193.001]
  • [Cites] Anal Chem. 2004 Mar 15;76(6):1550-9 [15018551.001]
  • [Cites] Anal Chem. 2004 Mar 15;76(6):1657-63 [15018564.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4270-6 [15205341.001]
  • [Cites] Science. 2004 Jul 2;305(5680):71-3 [15232100.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):3930-4 [15253626.001]
  • [Cites] Anal Chem. 2004 Aug 1;76(15):4271-8 [15283560.001]
  • [Cites] J Card Fail. 2004 Aug;10(4):334-8 [15309701.001]
  • [Cites] J Am Soc Mass Spectrom. 2004 Oct;15(10):1499-508 [15465363.001]
  • [Cites] J Lipid Res. 1983 Apr;24(4):456-60 [6854152.001]
  • [Cites] J Lipid Res. 1984 Jul;25(7):738-49 [6481246.001]
  • [Cites] Lipids. 1987 Jul;22(7):480-9 [3626775.001]
  • [Cites] J Lipid Res. 1994 Jun;35(6):1102-14 [8077849.001]
  • [Cites] Anal Chem. 1994 Nov 15;66(22):3977-82 [7810900.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2028-34 [9329967.001]
  • [Cites] Anal Chem. 1997 Dec 1;69(23):4751-60 [9406525.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):80-4 [9892190.001]
  • [Cites] Anal Biochem. 1999 Feb 1;267(1):46-56 [9918654.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):279-86 [15591226.001]
  • [Cites] J Mass Spectrom. 2005 Aug;40(8):985-99 [16106340.001]
  • [Cites] Angew Chem Int Ed Engl. 2005 Nov 4;44(43):7094-7 [16259018.001]
  • [Cites] Analyst. 2005 Dec;130(12):1624-33 [16284661.001]
  • [Cites] J Chromatogr A. 2006 Mar 31;1110(1-2):86-94 [16480731.001]
  • [Cites] Chem Commun (Camb). 2006 Apr 28;(16):1709-11 [16609779.001]
  • [Cites] J Proteome Res. 2006 May;5(5):1107-16 [16674100.001]
  • [Cites] Rapid Commun Mass Spectrom. 2006;20(10):1577-84 [16628593.001]
  • [Cites] Rapid Commun Mass Spectrom. 2006;20(18):2717-27 [16912984.001]
  • [Cites] J Lipid Res. 2006 Oct;47(10):2101-11 [16902246.001]
  • [Cites] Rapid Commun Mass Spectrom. 2006;20(22):3403-8 [17051609.001]
  • [Cites] Angew Chem Int Ed Engl. 2006 Nov 6;45(43):7188-92 [17001721.001]
  • [Cites] Anal Bioanal Chem. 2007 Jan;387(2):539-49 [16821030.001]
  • [Cites] Anal Chem. 2007 Mar 15;79(6):2199-206 [17302385.001]
  • [Cites] Anal Chem. 2007 May 1;79(9):3514-8 [17394289.001]
  • [Cites] Analyst. 2007 May;132(5):461-7 [17471393.001]
  • [Cites] Anal Chem. 2007 Nov 1;79(21):8098-106 [17900146.001]
  • [Cites] Anal Chem. 2008 Apr 15;80(8):2780-8 [18314967.001]
  • (PMID = 19150258.001).
  • [ISSN] 1873-376X
  • [Journal-full-title] Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
  • [ISO-abbreviation] J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM058008-07; United States / NIGMS NIH HHS / GM / R01 GM058008; United States / NIGMS NIH HHS / GM / 5R01 GM58008-07; United States / NIGMS NIH HHS / GM / R01 GM058008-07
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Lipids
  • [Other-IDs] NLM/ NIHMS227068; NLM/ PMC2921711
  •  go-up   go-down


21. Piazuelo E, Cebrián C, Escartín A, Jiménez P, Soteras F, Ortego J, Lanas A: Superoxide dismutase prevents development of adenocarcinoma in a rat model of Barrett's esophagus. World J Gastroenterol; 2005 Dec 21;11(47):7436-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superoxide dismutase prevents development of adenocarcinoma in a rat model of Barrett's esophagus.
  • AIM: To test whether antioxidant treatment could prevent the progression of Barrett's esophagus to adenocarcinoma.
  • METHODS: In a rat model of gastroduodenoesophageal reflux by esophagojejunal anastomosis with gastric preservation, groups of 6-10 rats were randomized to receive treatment with superoxide dismutase (SOD) or vehicle and followed up for 4 mo.
  • Rat's esophagus was assessed by histological analysis, superoxide anion and peroxinitrite generation, SOD levels and DNA oxidative damage.
  • The process was associated with a progressive presence of intestinal metaplasia beyond the anastomotic area (9% 1st mo and 50% 4th mo) (94% at the anastomotic level) and adenocarcinoma (11% 1st mo and 60% 4th mo).
  • Exogenous administration of SOD decreased mucosal superoxide levels, increased mucosal SOD levels and reduced the risk of developing intestinal metaplasia beyond the anastomotic area (odds ratio = 0.326; 95%CI: 0.108-0.981; P = 0.046), and esophageal adenocarcinoma (odds ratio = 0.243; 95%CI: 0.073-0.804; P = 0.021).
  • CONCLUSION: Superoxide dismutase prevents the progression of esophagitis to Barrett's esophagus and adenocarcinoma in this rat model of gastrointestinal reflux, supporting a role of antioxidants in the chemoprevention of esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / prevention & control. Barrett Esophagus / drug therapy. Esophageal Neoplasms / prevention & control. Free Radical Scavengers / pharmacology. Superoxide Dismutase / pharmacology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437713.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Free Radical Scavengers; EC 1.15.1.1 / Superoxide Dismutase
  • [Other-IDs] NLM/ PMC4725177
  •  go-up   go-down


22. Cereda S, Reni M: Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer. J Chemother; 2008 Aug;20(4):509-12
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Between November 2004 and November 2005, 10 patients (median age 59; median KPS 80) with metastatic pancreatic adenocarcinoma, progressive disease after gemcitabine-containing chemotherapy, KPS >50, adequate organ function, were treated with weekly docetaxel at 30 mg/m-(2) until progressive disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Salvage Therapy. Taxoids / therapeutic use


23. Bonde P, Sui G, Dhara S, Wang J, Broor A, Kim IF, Wiley JE, Marti G, Duncan M, Jaffee E, Montgomery E, Maitra A, Harmon JW: Cytogenetic characterization and gene expression profiling in the rat reflux-induced esophageal tumor model. J Thorac Cardiovasc Surg; 2007 Mar;133(3):763-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic characterization and gene expression profiling in the rat reflux-induced esophageal tumor model.
  • OBJECTIVES: The reasons for the increasing incidence of esophageal adenocarcinoma are not clear.
  • A causal relation between gastroesophageal reflux disease and esophageal adenocarcinoma has been suggested.
  • Support for this comes from the development of esophageal adenocarcinoma in the rat reflux model.
  • The experiment was terminated at 9 months, and rat esophagi were harvested for histopathologic documentation of reflux-associated changes and evidence of tumor formation.
  • [MeSH-major] Adenocarcinoma / genetics. Cell Transformation, Neoplastic / pathology. Esophageal Neoplasms / genetics. Gastroesophageal Reflux / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320581.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Grant] United States / FIC NIH HHS / TW / D43 TW06176
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary
  •  go-up   go-down


24. Cereda S, Reni M, Rognone A, Ghidini M, Belli C, Longoni S, Fugazza C, Brioschi M, Nicoletti R, Balzano G, Passoni P, Villa E: XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer. Anticancer Res; 2010 Nov;30(11):4785-90
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: More than half of patients with pancreatic adenocarcinoma (PA) are candidates for further treatment when they experience upfront treatment failure.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy. Salvage Therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21115942.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


25. Reni M, Cereda S, Mazza E, Passoni P, Nicoletti R, Balzano G, Zerbi A, Arcidiacono PG, Staudacher C, Di Carlo V: PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. Am J Clin Oncol; 2008 Apr;31(2):145-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The activity and safety of this combination regimen were assessed by means of an observational study in a population of patients with progressive or recurrent pancreatic adenocarcinoma after gemcitabine-containing chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy. Salvage Therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18391598.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


26. Reni M, Cereda S, Galli L: PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen. Cancer Lett; 2007 Oct 18;256(1):25-8
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17561341.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 23
  •  go-up   go-down


27. Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V: Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol; 2005 Jun;6(6):369-76
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Patients with advanced pancreatic adenocarcinoma have a poor response, progression-free survival, and overall survival with standard treatment.
  • INTERPRETATION: The PEFG regimen could be considered for treatment of advanced pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2005 Jun;6(6):352-3 [15948320.001]
  • (PMID = 15925814.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


28. Valentini V, Calvo F, Reni M, Krempien R, Sedlmayer F, Buchler MW, Di Carlo V, Doglietto GB, Fastner G, Garcia-Sabrido JL, Mattiucci G, Morganti AG, Passoni P, Roeder F, D'Agostino GR: Intra-operative radiotherapy (IORT) in pancreatic cancer: joint analysis of the ISIORT-Europe experience. Radiother Oncol; 2009 Apr;91(1):54-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Pancreatic Neoplasms / radiotherapy. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18762346.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Ireland
  •  go-up   go-down


29. Mercalli A, Sordi V, Formicola R, Dandrea M, Beghelli S, Scarpa A, Di Carlo V, Reni M, Piemonti L: A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer. Br J Cancer; 2007 May 7;96(9):1358-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gemcitabine (GEM)-based chemotherapy is regarded as the standard treatment of pancreatic adenocarcinoma, but yields a very limited disease control.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2002 Jul 15;87(2):161-7 [12107836.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3130-6 [12118027.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3270-5 [12149301.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1185-91 [12181240.001]
  • [Cites] Cancer. 2002 Aug 15;95(4 Suppl):928-32 [12209673.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 20):9-16 [12577228.001]
  • [Cites] Br J Cancer. 2003 Apr 22;88(8):1180-4 [12698181.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3296-302 [12947065.001]
  • [Cites] World J Surg. 2003 Oct;27(10):1075-84 [12925907.001]
  • [Cites] Expert Rev Anticancer Ther. 2003 Oct;3(5):587-93 [14599083.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1430-8 [15084616.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2936-43 [15131028.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):133-8 [15221998.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3776-83 [15365074.001]
  • [Cites] Cancer. 1990 May 15;65(10):2207-12 [2189551.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):491-8 [1999720.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):950-8 [8098059.001]
  • [Cites] Cancer Treat Rev. 1993 Oct;19(4):351-86 [8106152.001]
  • [Cites] J Clin Oncol. 1993 Nov;11(11):2194-204 [8229134.001]
  • [Cites] J Natl Cancer Inst. 1994 Oct 19;86(20):1517-24 [7932806.001]
  • [Cites] Ann Oncol. 1995 Feb;6(2):129-32 [7786820.001]
  • [Cites] Eur J Cancer. 1995 Jun;31A(6):882-7 [7646915.001]
  • [Cites] Semin Oncol. 1996 Apr;23(2):220-8 [8623058.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1495-503 [8622063.001]
  • [Cites] Am J Health Syst Pharm. 1997 Jan 15;54(2):162-70; quiz 197-8 [9117804.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1116-23 [9067281.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(6):521-31 [9118464.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Clin Pharmacokinet. 1997 Oct;33(4):245-59 [9342501.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1470-8 [9552054.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(1):71-6 [9619761.001]
  • [Cites] Br J Cancer. 1998 Nov;78(9):1188-93 [9820178.001]
  • [Cites] Biochem Pharmacol. 1998 Nov 15;56(10):1315-22 [9825730.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1261-8 [10189130.001]
  • [Cites] Br J Cancer. 1999 Jun;80(7):981-90 [10362105.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3671-6 [10446980.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):796-807 [10505042.001]
  • [Cites] Oncology. 2004;67(2):93-7 [15539911.001]
  • [Cites] Cancer Invest. 2004;22(5):688-96 [15581049.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Jun;55(6):522-30 [15754203.001]
  • [Cites] Lancet Oncol. 2005 Jun;6(6):369-76 [15925814.001]
  • [Cites] Am J Clin Oncol. 2005 Aug;28(4):345-50 [16062075.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1639-45 [16087696.001]
  • [Cites] Semin Oncol. 1999 Apr;26(2 Suppl 6):48-54 [10598555.001]
  • [Cites] Semin Oncol. 1999 Apr;26(2 Suppl 6):82-8 [10598560.001]
  • [Cites] Semin Oncol. 1999 Apr;26(2 Suppl 6):99-104 [10598563.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):101-3 [10690396.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1748-57 [10764436.001]
  • [Cites] Pharmacol Ther. 2000 Aug-Sep;87(2-3):227-53 [11008002.001]
  • [Cites] Anticancer Drugs. 2000 Sep;11(8):635-8 [11081455.001]
  • [Cites] Drugs. 2000 Oct;60(4):895-924 [11085200.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):600-3 [11237378.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6D):5209-12 [11326696.001]
  • [Cites] Curr Opin Oncol. 2001 Jul;13(4):275-86 [11429486.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3447-55 [11481349.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Aug;48(2):141-4 [11561780.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):233-9 [11801564.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):140-5 [12007952.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):785-91 [16508631.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):587-92 [16909140.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):532-9 [17255275.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):498-503 [17158774.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):1037-42 [8094996.001]
  • (PMID = 17426706.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2360188
  •  go-up   go-down


30. Reni M: Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing? World J Gastroenterol; 2010 Oct 21;16(39):4883-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper discusses the rationale for phase III testing of neoadjuvant therapy in patients affected by resectable pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials, Phase III as Topic. Pancreatectomy. Pancreatic Neoplasms / therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2007 Feb;59(3):361-7 [16807732.001]
  • [Cites] Pancreatology. 2006;6(5):454-63 [16847383.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Anticancer Drugs. 2007 Mar;18(3):263-71 [17264757.001]
  • [Cites] Ann Surg Oncol. 2007 Jul;14(7):2088-96 [17453298.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jan;61(1):167-75 [17440727.001]
  • [Cites] JAMA. 2008 Mar 5;299(9):1019-26 [18319412.001]
  • [Cites] J Chemother. 2008 Feb;20(1):119-25 [18343754.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3487-95 [18640929.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3496-502 [18640930.001]
  • [Cites] Eur J Surg Oncol. 2009 Jun;35(6):600-4 [19131205.001]
  • [Cites] Cancer. 2009 Jun 15;115(12):2630-9 [19353729.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3778-85 [19581537.001]
  • [Cites] Anticancer Drugs. 2010 Apr;21(4):459-64 [20110805.001]
  • [Cites] J Clin Oncol. 2010 Apr 1;28(10):1645-51 [20194854.001]
  • [Cites] Cancer Invest. 2007;25(7):594-8 [17852117.001]
  • [Cites] Cancer Chemother Pharmacol. 2012 Jan;69(1):115-23 [21626049.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Ann Oncol. 2000 Nov;11(11):1399-403 [11142479.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2679-86 [11352960.001]
  • [Cites] Ann Surg Oncol. 2001 Dec;8(10):758-65 [11776488.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):902-10 [11920457.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2537-44 [12011133.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3130-6 [12118027.001]
  • [Cites] Am J Surg. 2003 May;185(5):476-80 [12727570.001]
  • [Cites] Ann Oncol. 2004 Mar;15(3):474-7 [14998851.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):437-43 [15380577.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] Stat Med. 1986 Sep-Oct;5(5):441-7 [3786998.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2124-33 [8374871.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):928-37 [9060530.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):317-23 [9440759.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1228-36 [15718320.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3509-16 [15908661.001]
  • [Cites] Lancet Oncol. 2005 Jun;6(6):369-76 [15925814.001]
  • [Cites] Oncology. 2005;68(2-3):239-45 [16015040.001]
  • [Cites] Ann Oncol. 2007 Jan;18(1):82-7 [17030546.001]
  • (PMID = 20954273.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2957595
  •  go-up   go-down


31. Nazarenko I, Rana S, Baumann A, McAlear J, Hellwig A, Trendelenburg M, Lochnit G, Preissner KT, Zöller M: Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res; 2010 Feb 15;70(4):1668-78
Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we used a rat adenocarcinoma model (AS-Tspan8) to explore the effects of exosomal Tspan8 on angiogenesis.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Animals. Antigens, Surface / genetics. Antigens, Surface / metabolism. Antigens, Surface / physiology. Cell Differentiation / drug effects. Cell Differentiation / genetics. Cell Membrane / metabolism. Cell Proliferation / drug effects. Cells, Cultured. Gene Expression Regulation, Neoplastic / drug effects. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. RNA, Small Interfering / pharmacology. Rats. Signal Transduction / drug effects. Signal Transduction / genetics. Tetraspanins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Res.2010 Aug 15;70(16):6683
  • (PMID = 20124479.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antigens, Surface; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 0 / Tetraspanins; 0 / Tspan8 protein, rat
  •  go-up   go-down


32. Chu QD, Sun L, Li J, Byrnes K, Chervenak D, DeBenedetti A, Mathis JM, Li BD: Rat adenocarcinoma cell line infected with an adenovirus carrying a novel herpes-simplex virus-thymidine kinase suicide gene construct dies by apoptosis upon treatment with ganciclovir. J Surg Res; 2007 Nov;143(1):189-94
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rat adenocarcinoma cell line infected with an adenovirus carrying a novel herpes-simplex virus-thymidine kinase suicide gene construct dies by apoptosis upon treatment with ganciclovir.
  • In this study, we investigated the in vitro activity of this suicide gene therapy against the rat Mat BIII breast adenocarcinoma cell line, and assessed whether apoptosis was the responsible mechanism of cell killing.
  • CONCLUSION: Suicide gene therapy targeting the overexpression of eIF4E induces apoptosis and cell death in rat Mat BIII mammary adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / therapy. Apoptosis / drug effects. Eukaryotic Initiation Factor-4E / metabolism. Ganciclovir / pharmacology. Genes, Transgenic, Suicide. Mammary Neoplasms, Animal / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950092.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Eukaryotic Initiation Factor-4E; 0 / Fluorescent Dyes; EC 2.7.1.21 / Thymidine Kinase; I223NX31W9 / Fluorescein-5-isothiocyanate; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


33. Reni M, Pasetto L, Aprile G, Cordio S, Bonetto E, Dell'Oro S, Passoni P, Piemonti L, Fugazza C, Luppi G, Milandri C, Nicoletti R, Zerbi A, Balzano G, Di Carlo V, Brandes AA: Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer; 2006 Mar 27;94(6):785-91
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients >18 years, PS >or=50, with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-containing chemotherapy, and progression-free survival (PFS) <12 months received a combination of raltitrexed (3 mg m(-2)) and oxaliplatin (130 mg m(-2)) every 3 weeks until progression, toxicity, or a maximum of six cycles.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1995 Jun;31A(6):882-7 [7646915.001]
  • [Cites] Cancer Invest. 1990;8(2):147-59 [2400936.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):593-600 [8879373.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):139-44 [9440735.001]
  • [Cites] Ann Oncol. 1998 Oct;9(10):1053-71 [9834817.001]
  • [Cites] Acta Oncol. 1998;37(7-8):651-9 [10050982.001]
  • [Cites] Int J Oncol. 1999 May;14(5):821-31 [10200331.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):236-47 [15258755.001]
  • [Cites] Oncology. 2004;67(2):93-7 [15539911.001]
  • [Cites] Cancer Invest. 2004;22(5):688-96 [15581049.001]
  • [Cites] Lancet Oncol. 2005 Jun;6(6):369-76 [15925814.001]
  • [Cites] Eur J Cancer. 1999 Jun;35(6):939-41 [10533475.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2293-300 [10829050.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5A):3259-64 [11062751.001]
  • [Cites] Anticancer Drugs. 2000 Sep;11(8):635-8 [11081455.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3447-55 [11481349.001]
  • [Cites] Oncologist. 2001;6(6):488-95 [11743211.001]
  • [Cites] Ann Oncol. 2002 May;13(5):716-20 [12075739.001]
  • [Cites] Br J Cancer. 2002 Jul 15;87(2):161-7 [12107836.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3270-5 [12149301.001]
  • [Cites] Ann Oncol. 2002 Jul;13(7):1072-9 [12176786.001]
  • [Cites] Br J Cancer. 2003 Apr 22;88(8):1180-4 [12698181.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3296-302 [12947065.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1430-8 [15084616.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):133-8 [15221998.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3776-83 [15365074.001]
  • [Cites] Invest New Drugs. 1996;13(4):355-8 [8824356.001]
  • (PMID = 16508631.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Quinazolines; 0 / Thiophenes; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; FCB9EGG971 / raltitrexed
  • [Other-IDs] NLM/ PMC2361378
  •  go-up   go-down


34. Kalaiselvan P, Vijayakumar S, Hemalatha K, Murkunde YV, Herbert RA, Wells MY: Mass in the lateral cervical-thoracic region in a male Wistar rat. Adenocarcinoma of the mammary gland. Lab Anim (NY); 2009 Sep;38(9):288-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mass in the lateral cervical-thoracic region in a male Wistar rat. Adenocarcinoma of the mammary gland.
  • [MeSH-major] Adenocarcinoma / veterinary. Animals, Laboratory. Mammary Neoplasms, Animal / pathology. Rodent Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19701177.001).
  • [ISSN] 0093-7355
  • [Journal-full-title] Lab animal
  • [ISO-abbreviation] Lab Anim (NY)
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


35. Takahashi S, Takeshita K, Seeni A, Sugiura S, Tang M, Sato SY, Kuriyama H, Nakadate M, Abe K, Maeno Y, Nagao M, Shirai T: Suppression of prostate cancer in a transgenic rat model via gamma-tocopherol activation of caspase signaling. Prostate; 2009 May 1;69(6):644-51
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of prostate cancer in a transgenic rat model via gamma-tocopherol activation of caspase signaling.
  • The purpose of the present study was to confirm effects of gamma-tocopherol on prostate cancer in the transgenic rat for adenocarcinoma of prostate (TRAP) model established in our laboratory.
  • However, quantitative evaluation of prostatic lesions demonstrated significantly suppression of sequential progression from PIN to adenocarcinoma in a dose-dependent manner, along with clear activation of caspases 3 and 7 in the ventral lobe in both experiments.
  • [MeSH-major] Adenocarcinoma / prevention & control. Prostatic Neoplasms / prevention & control. gamma-Tocopherol / therapeutic use

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19143023.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Ceramides; 0 / Isoenzymes; 1406-66-2 / Tocopherols; 8EF1Z1238F / gamma-Tocopherol; EC 3.1.3.- / tartrate-resistant acid phosphatase; EC 3.1.3.2 / Acid Phosphatase
  •  go-up   go-down


36. Klingbeil P, Marhaba R, Jung T, Kirmse R, Ludwig T, Zöller M: CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance. Mol Cancer Res; 2009 Feb;7(2):168-79
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To study the underlying mechanism, stable knockdown clones with deletion of exon v7 containing CD44 isoforms (CD44v(kd)) of the highly metastatic rat adenocarcinoma line BSp73ASML (ASML(wt)) were established.
  • [MeSH-major] Adenocarcinoma / secondary. Antigens, CD44 / genetics. Apoptosis / genetics. Cell Adhesion / genetics. Extracellular Matrix / metabolism. Lung Neoplasms / secondary. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19208744.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Cross-Linking Reagents; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


37. Krupka TM, Dremann D, Exner AA: Time and dose dependence of pluronic bioactivity in hyperthermia-induced tumor cell death. Exp Biol Med (Maywood); 2009 Jan;234(1):95-104
Hazardous Substances Data Bank. POLOXALENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DHD/K12/TRb rat adenocarcinoma cells were exposed to low-grade hyperthermia at 43 degrees C with or without Pluronic P85 or Pluronic L61.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Apr 1;355(9210):1119-25 [10791373.001]
  • [Cites] J Control Release. 2008 Sep 10;130(2):98-106 [18534704.001]
  • [Cites] Radiology. 2000 Oct;217(1):119-26 [11012432.001]
  • [Cites] Int J Hyperthermia. 2001 Mar-Apr;17(2):97-105 [11252361.001]
  • [Cites] Eur J Ultrasound. 2001 Jun;13(2):129-47 [11369525.001]
  • [Cites] J Vasc Interv Radiol. 2001 Jul;12(7):823-33 [11435538.001]
  • [Cites] Radiology. 2001 Aug;220(2):420-7 [11477246.001]
  • [Cites] Radiology. 2001 Oct;221(1):159-66 [11568334.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Nov;299(2):483-93 [11602658.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1987-97 [11747344.001]
  • [Cites] J Pharm Sci. 2002 Jan;91(1):157-70 [11782905.001]
  • [Cites] Front Radiat Ther Oncol. 2002;36:171-6 [11842749.001]
  • [Cites] Radiology. 2002 Mar;222(3):797-804 [11867804.001]
  • [Cites] Curr Probl Surg. 2002 May;39(5):449-571 [12019420.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Jul;43(1):33-56 [12098606.001]
  • [Cites] Lasers Surg Med. 2002;31(3):158-63 [12224088.001]
  • [Cites] J Urol. 2003 Jan;169(1):338-46 [12478186.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Feb;304(2):845-54 [12538842.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Apr;125(4):929-37 [12698158.001]
  • [Cites] Chemistry. 2003 Aug 18;9(16):3930-6 [12916119.001]
  • [Cites] J Control Release. 2003 Aug 28;91(1-2):75-83 [12932639.001]
  • [Cites] Pharm Res. 2003 Oct;20(10):1581-90 [14620511.001]
  • [Cites] Radiology. 2004 Feb;230(2):450-8 [14688400.001]
  • [Cites] J Vasc Interv Radiol. 2004 Mar;15(3):269-74 [15028812.001]
  • [Cites] Radiologe. 2004 Apr;44(4):301-9 [15042293.001]
  • [Cites] Annu Rev Biochem. 1986;55:1151-91 [2427013.001]
  • [Cites] New Biol. 1991 Nov;3(11):1106-20 [1777484.001]
  • [Cites] Bioconjug Chem. 1996 Mar-Apr;7(2):209-16 [8983343.001]
  • [Cites] Nihon Rinsho. 1996 Jul;54(7):1949-54 [8741693.001]
  • [Cites] Radiology. 1997 Jan;202(1):205-10 [8988212.001]
  • [Cites] J Vasc Interv Radiol. 1998 Jan-Feb;9(1 Pt 1):101-11 [9468403.001]
  • [Cites] Prostate. 1998 Feb 15;34(3):195-202 [9492848.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3513-8 [9520397.001]
  • [Cites] AJR Am J Roentgenol. 1998 Apr;170(4):1015-22 [9530052.001]
  • [Cites] Ann Surg. 1998 Apr;227(4):559-65 [9563546.001]
  • [Cites] Hum Cell. 1998 Sep;11(3):167-74 [10086278.001]
  • [Cites] FEBS Lett. 1999 Mar 5;446(1):194-8 [10100641.001]
  • [Cites] Radiology. 1999 Aug;212(2):459-66 [10429704.001]
  • [Cites] FEBS Lett. 1999 Aug 6;456(2):339-42 [10456335.001]
  • [Cites] Pharm Res. 1999 Sep;16(9):1373-9 [10496652.001]
  • [Cites] Biochemistry. 2005 Mar 15;44(10):4042-54 [15751981.001]
  • [Cites] J Control Release. 2005 Aug 18;106(1-2):188-97 [15951044.001]
  • [Cites] FEBS J. 2005 Dec;272(23):6077-86 [16302971.001]
  • [Cites] Invest Radiol. 2006 Apr;41(4):422-7 [16523026.001]
  • [Cites] Mol Ther. 2006 Apr;13(4):804-13 [16199206.001]
  • [Cites] Paediatr Anaesth. 2006 Aug;16(8):890-1 [16884475.001]
  • [Cites] Invest Radiol. 2006 Dec;41(12):890-7 [17099428.001]
  • [Cites] J Surg Res. 2007 May 15;139(2):176-81 [17336331.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Mar;5(3):339-44 [17439762.001]
  • [Cites] Exp Biol Med (Maywood). 2007 Jul;232(7):950-7 [17609512.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Aug;19(6):418-26 [17493790.001]
  • [Cites] Abdom Imaging. 2007 May-Jun;32(3):332-8 [16933116.001]
  • [Cites] J Mol Cell Cardiol. 2007 Nov;43(5):616-26 [17884089.001]
  • [Cites] Cell Biochem Funct. 2007 Nov-Dec;25(6):669-72 [16933368.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Dec;19(10):805-6 [17892927.001]
  • [Cites] Radiology. 2008 Mar;246(3):796-803 [18309015.001]
  • [Cites] J Colloid Interface Sci. 2008 Jun 1;322(1):263-73 [18377918.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2452-63 [10861420.001]
  • (PMID = 18997100.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA136857; United States / NCI NIH HHS / CA / R01 CA136857-01; United States / NCI NIH HHS / CA / R01CA1118399
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / pluronic L61; 106392-12-5 / Poloxamer; 8L70Q75FXE / Adenosine Triphosphate; 9003-11-6 / Poloxalene
  • [Other-IDs] NLM/ NIHMS359379; NLM/ PMC3293626
  •  go-up   go-down


38. Yip SC, El-Sibai M, Coniglio SJ, Mouneimne G, Eddy RJ, Drees BE, Neilsen PO, Goswami S, Symons M, Condeelis JS, Backer JM: The distinct roles of Ras and Rac in PI 3-kinase-dependent protrusion during EGF-stimulated cell migration. J Cell Sci; 2007 Sep 1;120(Pt 17):3138-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined PI 3-kinase-dependent protrusion in MTLn3 rat adenocarcinoma cells.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17698922.001).
  • [ISSN] 0021-9533
  • [Journal-full-title] Journal of cell science
  • [ISO-abbreviation] J. Cell. Sci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA100324; United States / NCI NIH HHS / CA / CA13330; United States / NIDDK NIH HHS / DK / T32 DK007513; United States / NIDDK NIH HHS / DK / T32 DK 07513; United States / NCI NIH HHS / CA / P01 CA 100324; United States / NCI NIH HHS / CA / P30 CA013330
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Phosphatidylinositol Phosphates; 0 / Recombinant Fusion Proteins; 0 / phosphatidylinositol 3,4,5-triphosphate; 62229-50-9 / Epidermal Growth Factor; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 3.6.5.2 / rac GTP-Binding Proteins; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS647771; NLM/ PMC4267689
  •  go-up   go-down


39. Cereda S, Rognone A, Mazza E, Fugazza C, Ceraulo D, Villa E, Reni M: Weekly epirubicin as salvage therapy in patients with gemcitabine-resistant advanced pancreatic cancer. J Chemother; 2009 Dec;21(6):698-700
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibiotics, Antineoplastic / therapeutic use. Epirubicin / therapeutic use. Pancreatic Neoplasms / drug therapy. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20071296.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine
  •  go-up   go-down






Advertisement